BioSpace News Archive

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) first virtual annual meeting, ACR Convergence 2020.

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that results from its KALM-2 pivotal Phase 3 trial of KORSUVA

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2020 at 4:00 PM Eastern Time.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company’s WristMotion Total Arthroplasty System received 510(k) clearance from the U.S. Food and Drug Administration.

Align Technology, Inc. announced the introduction of Invisalign G8 with SmartForce Aligner Activation, the latest of the company’s biomechanics innovations.

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter after market close on Wednesday, November 4, 2020.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present at the following investor conferences next month:

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2020, after the market close on Wednesday, October 28, 2020.

Avantor, Inc. announced that its Board of Directors has declared a quarterly cash dividend to holders of its 6.250% Series A Mandatory Convertible Preferred Stock of $0.78 per share at a rate per share of 1.560%, payable on November 15, 2020 to holders of record on November 1, 2020.